Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure.
Compr Ther
May 2007
Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA.
A 55-yr-old woman with a history of B-cell lymphoma of the nasopharynx diagnosed in March 1999 eventually underwent submyeloablative allogeneic stem cell transplantation from a sibling donor in December 2002 after conventional treatment options were exhausted. The treatment approach was somewhat altered by the fact that the patient was a practicing Jehovah's Witness and refused blood-blood product transfusion. The course of her treatment was unremarkable until around day 100 posttransplant when she developed graft failure, leading to severe anemia.
View Article and Find Full Text PDFA natural compound (reuterin) produced by Lactobacillus reuteri for hemoglobin polymerization as a blood substitute.
Biotechnol Bioeng
July 2004
Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan, Republic of China.
Stroma-free hemoglobin (Hb) has been modified by pyridoxylation and followed by polymerization with glutaraldehyde as a blood substitute. Nevertheless, the reaction rate of pyridoxylated Hb (PLP-Hb) with glutaraldehyde is too fast to control its molecular weight distribution. Additionally, it was reported that glutaraldehyde is cytotoxic even at low doses.
View Article and Find Full Text PDFNew artificial oxygen carriers made of pegulated polymerised pyridoxylated porcine haemoglobin (P(4)Hb).
Comp Biochem Physiol A Mol Integr Physiol
May 2002
Bereich Klinische Physiologie, Universitaet Witten/Herdecke, Alfred-Herrhausen-Strasse 50, D-58455 Witten (Ruhr), Germany.
Oxygen-carrying plasma expanders are designed for use as iso-oncotic 'blood substitutes' to combat oxygen deficiencies caused by blood loss. In contrast, a hypo-oncotic artificial oxygen carrier can be added to existing blood - as a 'blood additive'. It has potential therapeutic use for deficiencies of oxygen which are not entailed by blood (volume) lack, and can therefore not be treated by a 'blood substitute', e.
View Article and Find Full Text PDFMolar masses and structure in solution of haemoglobin hyperpolymers--a common calibration of size exclusion chromatography of these artificial oxygen carriers.
Artif Cells Blood Substit Immobil Biotechnol
November 1997
Institut für Physiologie und Pathophysiologie, Johannes Gutenberg-Universität, Mainz, Germany.
We are developing artificial oxygen carriers for medical use, based on synthetic polymers--so-called hyperpolymers--obtained by cross-linking mammalian haemoglobins. One requirement with respect to the polymers is that they should not increase the oncotic pressure of blood remarkably--this can be realized by high molecular weights of the polymers with a narrow distribution. They may act as a oxygen transporting blood additive, and--in combination with a plasma expander--as a blood substitute.
View Article and Find Full Text PDFDetection of residual polyethylene glycol derivatives in pyridoxylated-hemoglobin-polyoxyethylene conjugate.
Artif Cells Blood Substit Immobil Biotechnol
May 1997
Apex Bioscience, Inc., Research Triangle Park, NC 27709, USA.
Purified hemoglobin solutions have been shown to cause renal toxicity in animals. Safe use of hemoglobin based therapeutics in humans requires modification of the hemoglobin molecule to prevent this toxicity. Hemoglobin modification may be accomplished by crosslinking the dimers within the hemoglobin tetramer or by derivatization of the alpha and/or beta subunits such that their size and/or charge prevents filtration by the glomeruli.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!